Sugi Predict

Sugi Predict / Compounds / SCHEMBL14938657

SCHEMBL14938657

SCHEMBL14938657

CC(C)(C)OC(=O)C1CCCN1[O]

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CASP3 P42574 1/20 0.43
▸ HSD17B10 Q99714 2/20 0.42
▸ HRH3 Q9Y5N1 1/20 0.39
▸ HPGD P15428 1/20 0.38
▸ ROCK2 O75116 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ EPHX1 P07099 1/20 0.36
▸ LMNA P02545 2/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CA2 P00918 1/20 0.35
▸ CHRM2 P08172 1/20 0.35
▸ CHRM1 P11229 1/20 0.35
▸ CHRM3 P20309 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2261903 0.95 CASP3 (0.43) CASP3HSD17B10HRH3HPGDROCK2
SCHEMBL14938601 0.89 HRH3 (0.41) CASP3HSD17B10HRH3HPGDSMN1; SMN2
SCHEMBL8490471 0.81 HSD17B10 (0.42) CASP3HSD17B10HRH3HPGDROCK2
SCHEMBL31016714 0.81 HSD17B10 (0.42) CASP3HSD17B10HRH3HPGDROCK2
SCHEMBL12084380 0.81 HSD17B10 (0.42) CASP3HSD17B10HRH3HPGDROCK2
SCHEMBL2677782 0.81 HSD17B10 (0.42) CASP3HSD17B10HRH3HPGDROCK2
SCHEMBL7362291 0.81 HSD17B10 (0.42) CASP3HSD17B10HRH3HPGDROCK2
SCHEMBL23999544 0.80 HSD17B10 (0.41) CASP3HSD17B10HRH3HPGDROCK2
SCHEMBL13166562 0.80 HSD17B10 (0.41) CASP3HSD17B10HRH3HPGDROCK2
SCHEMBL10211022 0.80 HSD17B10 (0.41) CASP3HSD17B10HRH3HPGDROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108699064-B Hexahydropyrazino-triazinone derivatives as kinase inhibitors UCB生物制药私人有限公司 2021-09-14 — — CN disclosed
US-RE48622-E1 Therapeutically active pyrazolo-pyrimidine derivatives UCB Biopharma SRL (BE) 2021-07-06 — — US disclosed
US-10450320-B2 Hexahydropyrazinotriazinone derivatives as kinase inhibitors UCB BIOPHARMA SPRL (BE) 2019-10-22 — — US disclosed
US-20180362532-A1 Hexahydropyrazinotriazinone Derivatives as Kinase Inhibitors UCB BIOPHARMA SPRL (BE) 2018-12-20 — — US disclosed
EP-3157922-B1 PYRAZOLO-PYRIDINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2018-11-28 — — EP disclosed
EP-3386984-A1 HEXAHYDROPYRAZINOTRIAZINONE DERIVATIVES AS KINASE INHIBITORS UCB Biopharma SPRL (BE) 2018-10-17 — — EP disclosed
US-10087180-B2 Pyrazolo-pyridine derivatives as kinase inhibitors UCB BIOPHARMA SPRL (BE) 2018-10-02 — — US disclosed
US-20180201622-A1 Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2018-07-19 — — US disclosed
US-10000497-B2 Fused bicyclic heteroaromatic derivatives as kinase inhibitors UCB BIOPHARMA SPRL (BY) 2018-06-19 — — US disclosed
US-9969748-B2 Fused bicyclic heteroaromatic derivatives as kinase inhibitors UCB BIOPHARMA SPRL (BE) 2018-05-15 — — US disclosed
US-20160194329-A1 Therapeutically Active Pyrazolo-Pyrimidine Derivatives UCB PHARMA SA (BE) 2016-07-07 — — US disclosed
WO-2015193168-A1 FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2015-12-23 — — WO disclosed
WO-2015193167-A1 PYRAZOLO-PYRIDINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2015-12-23 — — WO disclosed
WO-2015193169-A1 FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2015-12-23 — — WO disclosed
EP-2935269-A1 THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES UCB Biopharma SPRL (BE) 2015-10-28 — — EP disclosed
US-9096614-B2 Therapeutically active thiazolo-pyrimidine derivatives UCB PHARMA SA (BE) 2015-08-04 — — US disclosed
US-20140315885-A1 Therapeutically Active Thiazolo-Pyrimidine Derivatives UCB PHARMA SA (BE) 2014-10-23 — — US disclosed
EP-2776445-A1 THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES UCB Pharma, S.A. (BE) 2014-09-17 — — EP disclosed
WO-2014096423-A1 THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES UCB PHARMA S.A. (BE) 2014-06-26 — — WO disclosed
WO-2013068458-A1 THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES UCB PHARMA S.A. (BE) 2013-05-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180201622-A1 Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors PI4KB, PI4KA, PI4K2B CASP3 467/4885HSD17B10 1390/4885HRH3 1916/4885
US-20160194329-A1 Therapeutically Active Pyrazolo-Pyrimidine Derivatives HAVCR2, TPMT, NFATC1 CASP3 68/4885HSD17B10 4095/4885HRH3 2098/4885
US-20140315885-A1 Therapeutically Active Thiazolo-Pyrimidine Derivatives TPMT, IFNG, IRF3 CASP3 428/4885HSD17B10 2837/4885HRH3 3779/4885
US-10087180-B2 Pyrazolo-pyridine derivatives as kinase inhibitors PI4KA, PI4KB, PI4K2A CASP3 723/4885HSD17B10 3656/4885HRH3 2486/4885
US-10450320-B2 Hexahydropyrazinotriazinone derivatives as kinase inhibitors PI4KA, PI4KB, PI4K2B CASP3 437/4885HSD17B10 1525/4885HRH3 1929/4885
US-20180362532-A1 Hexahydropyrazinotriazinone Derivatives as Kinase Inhibitors PI4KA, PI4KB, PI4K2B CASP3 437/4885HSD17B10 1525/4885HRH3 1929/4885
US-10000497-B2 Fused bicyclic heteroaromatic derivatives as kinase inhibitors PI4KB, PI4KA, PI4K2B CASP3 525/4885HSD17B10 1492/4885HRH3 1669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.